Prostate cancer is the most common non-skin cancer in men. Biomarker-driven research — from PSA-based screening to PSMA-targeted theranostics — is transforming diagnosis and treatment. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO
PSA / KLK3
Prostate-Specific Antigen
The most widely used prostate cancer screening biomarker. 27 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.
Antibodies • Biosimilars • Proteins
PSMA
FOLH1 / GCPII
Overexpressed in prostate cancer; therapeutic and imaging target (lutetium-177 PSMA). 49 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.
Antibodies • Biosimilars • Proteins
AR
Androgen Receptor
Central driver of prostate cancer; target of enzalutamide, abiraterone. 75 products. Validated: Blocking, ELISA, FC, IHC, WB.
Antibodies • Biosimilars • Proteins
ERG
ETS Transcription Factor
TMPRSS2-ERG fusion in ~50% of prostate cancers. IHC surrogate marker. 14 products. Validated: ELISA, IHC, WB.
Antibodies • Proteins
TMPRSS2
Transmembrane Serine Protease
Fusion partner in TMPRSS2-ERG rearrangement. 13 products. Validated: ELISA, IHC, WB.
Antibodies • Proteins
STEAP
Six-Transmembrane Protein
Emerging ADC target with prostate cancer specificity. 16 products. Validated: Blocking, ELISA, FC, IHC, WB.
Antibodies • Biosimilars • Proteins
PD-L1
CD274
Checkpoint target for immunotherapy stratification. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.
Antibodies • Biosimilars • Proteins
PTEN
Tumor Suppressor
PTEN loss associated with aggressive disease and PI3K/AKT activation. 6 products. Validated: ELISA, IHC, WB.
Antibodies • Proteins
IHC-Validated AntibodiesAntibodies with IHC validation available for: PSA, PSMA, AR, ERG, TMPRSS2, STEAP. See individual product pages for clone details and recommended dilutions.
Flow Cytometry ReadyFC-validated antibodies available for: PSA, PSMA, AR, STEAP, PD-L1. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.
Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: PSA, PSMA, AR, STEAP, PD-L1.
Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.
What PD-L1 reagents do you offer?
We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).
What AR reagents do you offer?
We offer 60 detection antibodies, 9 research-grade biosimilar proteins, and 6 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), N430/20 (IHC, WB; unconjugated), N430/26 (IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Avdoralimab, CD88/C5AR1 (ADC-1004), CD88/C5AR1 (MOR210)).
What PSMA reagents do you offer?
We offer 22 detection antibodies, 14 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A097 (ELISA, IHC, WB; unconjugated), 1A098 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Pasotuxizumab, HuJ591-Gsmab, Rosopatamab).
What PSA / KLK3 reagents do you offer?
We offer 23 detection antibodies, 2 research-grade biosimilar proteins, and 2 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A553 (ELISA, IHC, WB; unconjugated), 1A554 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Lanadelumab, Navenibart).
Can I get custom antibodies for novel targets?
Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.
中文
English
한국어
日本語
Español
Français
Русский
